Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma

被引：0

作者：

Daisuke Minakata

Tadao Ishida

Kiyoshi Ando

Rikio Suzuki

Junji Tanaka

Shotaro Hagiwara

Revathi Ananthakrishnan

Shigeki Kuwayama

Mitsufumi Nishio

Yoshinobu Kanda

Kenshi Suzuki

机构：

[1] Jichi Medical University,Division of Hematology, Department of Medicine

[2] Japanese Red Cross Medical Center,Department of Hematology

[3] Tokai University School of Medicine,Department of Hematology and Oncology

[4] Tokyo Women’s Medical University,Department of Hematology

[5] University of Tsukuba,Faculty of Medicine

[6] Bristol Myers Squibb,undefined

[7] Bristol Myers Squibb K.K,undefined

来源：

International Journal of Hematology | 2023年 / 117卷

关键词：

Relapsed/refractory multiple myeloma; CAR T cell therapy; Japanese patients; Idecabtagene-vicleucel; Triple-class exposed;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：729 / 737

页数：8

共 50 条

[1] Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma
Minakata, Daisuke
Ishida, Tadao
Ando, Kiyoshi
Suzuki, Rikio
Tanaka, Junji
Hagiwara, Shotaro
Ananthakrishnan, Revathi
Kuwayama, Shigeki
Nishio, Mitsufumi
Kanda, Yoshinobu
Suzuki, Kenshi
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (05) : 729 - 737
[2] Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma in the pivotal phase 2 KarMMa study
Weisel, K.
Manier, S.
Kansagra, A.
Anderson, Jr L. D.
Berdeja, J.
Jagannath, S.
Lin, Y.
Lonial, S.
Shah, N.
Raje, N.
Siegel, D.
Oriol, A.
Truppel-Hartmann, A.
Rowe, E.
Patel, P.
Agarwal, A.
Campbell, T. B.
Rodriguez-Otero, P.
Munshi, N.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 179 - 180
[3] Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma
Kansagra, Ankit
Lin, Yi
Berdeja, Jesus G.
Shah, Nina
Oriol, Albert
Yakoub-Agha, Ibrahim
Einsele, Hermann
Rambaldi, Alessandro
Truppel-Hartmann, Anna
Rowe, Everton
Wang, Julie
Agarwal, Amit
Campbell, Timothy B.
Lonial, Sagar
BLOOD, 2020, 136
[4] Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis
Berdeja, Jesus G.
Raje, Noopur S.
Siegel, David S.
Lin, Yi
Anderson, Larry D., Jr.
Rodriguez-Otero, Paula
Manier, Salomon
Einsele, Hermann
Cavo, Michele
Truppel-Hartmann, Anna
Rowe, Everton
Sanford, Jill
Wang, Julie
Campbell, Timothy B.
Jagannath, Sundar
BLOOD, 2020, 136
[5] Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study
Raje, Noopur S.
Siegel, David S.
Jagannath, Sundar
Lonial, Sagar
Munshi, Nikhil C.
Moreau, Philippe
Goldschmidt, Hartmut
Cavo, Michele
Truppel-Hartmann, Anna
Rowe, Everton
Huang, Liping
Agarwal, Amit
Wang, Julie
Campbell, Timothy B.
San-Miguel, Jesus F.
Reece, Donna E.
BLOOD, 2020, 136
[6] Efficacy and Safety of Idecabtagene vicleucel (ide-cel, bb2121) in Elderly Patients (Pts) with Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa Subgroup Analysis
Einsele, Hermann
Berdeja, Jesus
Raje, Noopur
Siegel, David
Lin, Yi
Anderson, Larry, Jr.
Rodriguez-Otero, Paula
Manier, Salomon
Cavo, Michele
Truppel-Hartmann, Anna
Rowe, Everton
Sanford, Jill
Wang, Julie
Campbell, Timothy
Jagannath, Sundar
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 53 - 53
[7] Efficacy and safety of Idecabtagene Vicleucel (ide-cel, bb2121) in elderly patients (Pts) with relapsed and refractory multiple myeloma (RRMM): KarMMa subgroup analysis
Einsele, H.
Berdeja, J.
Raje, N. S.
Siegel, D. S.
Lin, Y.
Anderson, L. D., Jr.
Rodriguez-Otero, P.
Manier, S.
Cavo, M.
Truppel-Hartmann, A.
Rowe, E.
Sanford, J.
Wang, J.
Campbell, T. B.
Jagannath, S.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 198 - 199
[8] CHARACTERISTICS OF NEUROTOXICITY ASSOCIATED WITH IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN PATIENTS WITH MULTIPLE MYELOMA IN RECALLING AND REFRACTORY OF THE PIVOTAL STUDY PHASE 2 KARMMA
Albert, Oriol
Salomon, Manier
Ankit, Kansagra
Larry, Anderson Jr D.
Jesus, Berdeja
Sundar, Jagannath
Yi, Lin
Sagar, Lonial
Nina, Shah
Noopur, Raje
David, Siegel
Anna, Truppel-Hartmann
Everton, Rowe
Payal, Patel
Amit, Agarwal
Timothy, Campbell B.
Paula, Rodriguez-Otero
Nikhil, Munshi
HAEMATOLOGICA, 2021, 106 (10) : 78 - 79
[9] Idecabtagene vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of High-Risk Subgroups in the KarMMa Study
Goldschmidt, Hartmut
Raje, Noopur
Siegel, David
Jagannath, Sundar
Lonial, Sagar
Munshi, Nikhil
Moreau, Philippe
Cavo, Michele
Truppel-Hartmann, Anna
Rowe, Everton
Huang, Liping
Agarwal, Amit
Wang, Julie
Campbell, Timothy
San-Miguel, Jesus
Reece, Donna
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 50 - 50
[10] Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study.
Manier, Salomon
Kansagra, Ankit J.
Anderson, Larry D., Jr.
Berdeja, Jesus G.
Jagannath, Sundar
Lin, Yi
Lonial, Sagar
Shah, Nina
Raje, Noopur S.
Siegel, David Samuel DiCapua
Oriol, Albert
Truppel-Hartmann, Anna
Rowe, Everton
Patel, Payal
Agarwal, Amit
Campbell, Timothy B.
Rodriguez-Otero, Paula
Munshi, Nikhil C.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →